1352623-96-1

Basic information

• Product Name: (S)-2-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-5-nitro-N-(1-phenylethyl)pyrimidin-4-amine
• Synonyms: (S)-2-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-5-nitro-N-(1-phenylethyl)pyrimidin-4-amine
• CAS NO: 1352623-96-1
• Molecular Weight: 378.366
• Mol File: 1352623-96-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (S)-2-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-5-nitro-N-(1-phenylethyl)pyrimidin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-5-nitro-N-(1-phenylethyl)pyrimidin-4-amine(1352623-96-1)
• EPA Substance Registry System: (S)-2-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-5-nitro-N-(1-phenylethyl)pyrimidin-4-amine(1352623-96-1)

Safety Data

• Hazardous Substances Data: 1352623-96-1(Hazardous Substances Data)

Upstream product

• 1313279-53-6 3-(4-chloro-5-nitropyrimidin-2-yl)-6-fluoroimidazo[1,2-a]pyridine 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 1220039-94-0 6-fluoroimidazo[1,2-a]pyridine-3-carboximidamide 
• 1134327-96-0 6-fluoroimidazo[1,2-a]pyridine-3-carbonitrile 
• 21717-96-4 2-amino-5-fluoropyridine 

Downstream Products

• 1352623-97-2 (S)-2-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-N⁴-(1-phenylethyl)pyrimidine-4,5-diamine 

Relevant articles and documents

Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases

Janus kinases (JAKs) have a key role in regulating the expression and function of relevant inflammatory cytokines involved in asthma and chronic obstructive pulmonary disease. Herein are described the design, synthesis, and pharmacological evaluation of a series of novel purinone JAK inhibitors with profiles suitable for inhaled administration. Replacement of the imidazopyridine hinge binding motif present in the initial compounds of this series with a pyridone ring resulted in the mitigation of cell cytotoxicity. Further systematic structure-activity relationship (SAR) efforts driven by structural biology studies led to the discovery of pyridone 34, a potent pan-JAK inhibitor with good selectivity, long lung retention time, low oral bioavailability, and proven efficacy in the lipopolysaccharide-induced rat model of airway inflammation by the inhaled route.

Heteroaryl imidazolone derivatives as jak inhibitors

New heteroaryl imidazolone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).